This HTML5 document contains 97 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n27http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n5http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/pdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/pubchem-compound/
n26http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/drugbank/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n32http://www.rxlist.com/cgi/generic2/
n15http://linked.opendata.cz/resource/drugbank/property/
n31http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00499/identifier/chemspider/
n19http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00499
rdf:type
n3:Drug
n3:description
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
n3:dosage
n10:271B5FF0-363D-11E5-9242-09173F13E4C5 n10:271B5FF1-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# "Link":http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Flutamide.htm
n3:group
approved
n3:halfLife
The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.
n3:indication
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
n3:manufacturer
n6:271B5FEE-363D-11E5-9242-09173F13E4C5 n6:271B5FEC-363D-11E5-9242-09173F13E4C5 n6:271B5FED-363D-11E5-9242-09173F13E4C5 n6:271B5FEB-363D-11E5-9242-09173F13E4C5 n6:271B5FE9-363D-11E5-9242-09173F13E4C5 n6:271B5FEA-363D-11E5-9242-09173F13E4C5
owl:sameAs
n26:DB00499 n29:DB00499
dcterms:title
Flutamide
adms:identifier
n12:46508874 n13:PA449685 n14:3397 n20:0555-0870-01 n21:HFT n22:C07653 n23:D00586 n24:DB00499 n27:5132 n28:3280 n30:Flutamide
n3:mechanismOfAction
Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen.
n3:packager
n6:271B5FE7-363D-11E5-9242-09173F13E4C5 n6:271B5FE8-363D-11E5-9242-09173F13E4C5 n6:271B5FE5-363D-11E5-9242-09173F13E4C5 n6:271B5FE6-363D-11E5-9242-09173F13E4C5 n6:271B5FDF-363D-11E5-9242-09173F13E4C5 n6:271B5FE0-363D-11E5-9242-09173F13E4C5 n6:271B5FDD-363D-11E5-9242-09173F13E4C5 n6:271B5FDE-363D-11E5-9242-09173F13E4C5 n6:271B5FE3-363D-11E5-9242-09173F13E4C5 n6:271B5FE4-363D-11E5-9242-09173F13E4C5 n6:271B5FE1-363D-11E5-9242-09173F13E4C5 n6:271B5FE2-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Flutamide and its metabolites are excreted mainly in the urine with only 4.2% of a single dose excreted in the feces over 72 hours.
n3:synonym
alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide 4'-Nitro-3'-trifluoromethylisobutyranilide FTA Eulexin Flutamida Niftolid Flutamid NFBA Niftolide Flutamidum Flutamide
n3:toxicity
In animal studies with flutamide alone, signs of overdose included hypoactivity, piloerection, slow respiration, ataxia, and/or lacrimation, anorexia, tranquilization, emesis, and methemoglobinemia.
n4:hasAHFSCode
n5:10-00-00
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
94-96%
n3:synthesisReference
Jack Lawrence James, Louis Frank Molnar, Jr., Tania E. Toney-Parker, "Processes for preparing flutamide compounds and compounds prepared by such processes." U.S. Patent US 6,228,401, issued November, 1976.
n7:hasConcept
n8:M0008651
foaf:page
n17:flutamide.html n31:eul1168.shtml n32:flutam.htm
n3:IUPAC-Name
n15:271B5FF6-363D-11E5-9242-09173F13E4C5
n3:InChI
n15:271B5FFC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n15:271B5FFB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n15:271B5FF8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n15:271B5FF9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n15:271B5FFA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n15:271B600C-363D-11E5-9242-09173F13E4C5 n15:271B5FF4-363D-11E5-9242-09173F13E4C5
n3:logP
n15:271B600E-363D-11E5-9242-09173F13E4C5 n15:271B5FF5-363D-11E5-9242-09173F13E4C5 n15:271B5FF2-363D-11E5-9242-09173F13E4C5
n3:logS
n15:271B5FF3-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n19:L02BB01
n3:H-Bond-Acceptor-Count
n15:271B6002-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n15:271B6003-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n15:271B5FFD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n15:271B5FFE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n15:271B6000-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n15:271B5FFF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n15:271B6001-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly and completely absorbed.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
13311-84-7
n3:category
n3:containedIn
n9:271B5FEF-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n15:271B6008-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n15:271B600A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n15:271B600B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n15:271B600D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n15:271B6007-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n15:271B6006-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n15:271B6009-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n15:271B5FF7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n15:271B6004-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n15:271B6005-363D-11E5-9242-09173F13E4C5